Media stories about Affimed N.V. (NASDAQ:AFMD) have trended somewhat positive this week, according to Accern. The research firm ranks the sentiment of press coverage by analyzing more than 20 million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Affimed N.V. earned a news sentiment score of 0.16 on Accern’s scale. Accern also gave press coverage about the biopharmaceutical company an impact score of 48.3453846500516 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the next few days.
These are some of the news stories that may have impacted Accern Sentiment’s analysis:
- FY2018 EPS Estimates for Affimed N.V. (AFMD) Increased by Analyst (americanbankingnews.com)
- What Does Affimed NV’s (AFMD) Share Price Indicate? (finance.yahoo.com)
- Affimed N.V. to Post Q1 2018 Earnings of ($0.20) Per Share, SunTrust Banks Forecasts (AFMD) (americanbankingnews.com)
- Leerink Swann Comments on Affimed N.V.’s FY2017 Earnings (AFMD) (americanbankingnews.com)
- Affimed NV :AFMD-US: Earnings Analysis: Q3, 2017 By the Numbers : November 8, 2017 (finance.yahoo.com)
Several equities research analysts recently issued reports on the stock. ValuEngine lowered shares of Affimed N.V. from a “sell” rating to a “strong sell” rating in a report on Friday, September 1st. Jefferies Group LLC reaffirmed a “hold” rating and set a $2.50 price target on shares of Affimed N.V. in a report on Thursday, July 27th.
Shares of Affimed N.V. (NASDAQ AFMD) opened at $2.07 on Tuesday. The company has a current ratio of 6.43, a quick ratio of 6.39 and a debt-to-equity ratio of 0.14. Affimed N.V. has a 1-year low of $1.65 and a 1-year high of $2.95.
TRADEMARK VIOLATION WARNING: This piece of content was reported by Stock Observer and is the property of of Stock Observer. If you are reading this piece of content on another publication, it was stolen and republished in violation of U.S. and international trademark and copyright laws. The correct version of this piece of content can be viewed at https://www.thestockobserver.com/2017/11/14/affimed-n-v-afmd-receiving-somewhat-favorable-news-coverage-report-finds.html.
Affimed N.V. Company Profile
Affimed N.V. is a clinical-stage biopharmaceutical company focused on discovering and developing cancer immunotherapies. The Company’s product candidates are developed in the field of immuno-oncology, which represents an approach to cancer research that seeks to harness the body’s own immune system to fight tumor cells.
Receive News & Ratings for Affimed N.V. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Affimed N.V. and related companies with MarketBeat.com's FREE daily email newsletter.